Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab vedotin plus anlotinib in previously treated HER2-variant advanced NSCLC
ChiCTR2300076386Phase 2Recruiting
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- Nov 2022
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of disitamab vedotin and anlotinib in non-small cell lung cancer (NSCLC), sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Primary endpoints: Maximum tolerated dose, Recommended phase 2 dose and 1 more. Started Nov 2022; status: recruiting.
02
Drugs
disitamab vedotinanlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2300076386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300076386.